Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains “off-label”. The COILSEAL, led by Cerrato et al., offers the first multicenter vision on hospital outcomes and mid-term followup of procedures using coils during coronary angioplasty. Data came from 17 high volume centers in Italy and Spain. 

The use of coils in coronary arteries presents two main indications: the first, and most common, is distal coronary perforation management, typically caused by inadvertent wire advancement into small or fragile territories, especially in the context of chronic total occlusions. These distal perforations are not treatable with coated stents and require precise occlusion strategy. The second indication is percutaneous closure of coronary aneurysms or fistulas, where coated stents can be technical or anatomically unfeasible. 

Technically speaking, coronary coiling is performed with micro catheters that allow positioning immediately above the point of extravasation and progressively deploying the coil until flow ceases completely. In the COILSEAL registry, the vast majority of devices were detachable coils (94%), because of their greater control during deployment. Instead, pushable coils were used exclusively in perforations and represented only 6% of cases.

Read also: Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization.

In coronary perforations, the average number of coils used per patient was 1.89 ± 0.87, with mean length 5.95 ± 3.72 cm and mean width 2.51 ± 0.90 mm. This choice of shorter length and smaller caliber responds to the need to occlude distant and frail segments without compromising side branches or inducing thrombotic propagation. 

The registry included 143 patients that needed coil implantation (0.06% of angioplasty procedures). 79% for perforations and 21% for aneurysms or fistulas. The cohort consisted of high risk patients, mean age 71, mostly men (71%) with high prevalence of multivessel disease and chronic occlusions.

The primary outcome was technical success, defined as absence of contrast extravasation at procedure end. Performance was remarkable, 95.7%, with no difference between perforations and aneurysms/fistulas. Procedural success (technical success with no major in-hospital clinical events) was lower for perforations (83.5% vs. 96.6%), which could be expected seeing the potential severity of this complication. Even so, in-hospital mortality was low, and the need for emergency surgery resulted exceptional (1.4%).

Read also: Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

At midterm followup (mean 2.4 years), the incidence of target vessel failure was 11.4%, with no significant differences between groups. There was higher rate of ischemia driven revascularization in cases of aneurysms or fistulas, consistent with the higher biological complexity of these lesions. Cardiac mortality remained low (4.9%) and the incidence of BARC major bleeding did not show significant differences. 

Conclusions

The COILSEAL registry outcomes have allowed us to concluded that the use of coils in the coronary setting is a safe, effective strategy with very high technical success rates, even in highly complex scenarios. Seeing its size and multicenter nature, this registry has contributed with robust scientific evidence to support a technique that, until now, had relied on small series and individual operator experience. 

Original Title: Contemporary Use of Coils During Percutaneous Coronary Intervention: Insights From the Multicenter COILSEAL Registry. 

Reference: Cerrato E, Piedimonte G, Franzino M, Marengo G, Bollati M, Zecchino S, Rutigliano D, Soriano F, Leoncini M, Mangione R, Sagazio E, Maiellaro F, Jeva F, Ussia GP, Scudiero F, Franzè A, Barbero U, Calderone D, Nicolino A, Ugo F, La Manna A, Costa F, Mazzarotto P, Amat-Santos IJ, Varbella F; CardioGroupVIII‐COILSEAL Study Group. Contemporary Use of Coils During Percutaneous Coronary Intervention: Insights From the Multicenter COILSEAL Registry. Catheter Cardiovasc Interv. 2025 Oct 21. doi: 10.1002/ccd.70233. Epub ahead of print. PMID: 41121637.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...